Towards a neuroprotective gene therapy for Parkinson’s disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model11Published on the World Wide Web on 10 October 2000.-Reference-Cited by-同舟云学术

Towards a neuroprotective gene therapy for Parkinson’s disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model11Published on the World Wide Web on 10 October 2000.

Published:2000-12 Issue:1-2 Volume:886 Page:82-98
ISSN:0006-8993
Container-title:Brain Research
language:en
Short-container-title:Brain Research

Author:

Björklund A.,Kirik D.,Rosenblad C.,Georgievska B.,Lundberg C.,Mandel R.J.

Publisher

Elsevier BV

Subject

Developmental Biology,Clinical Neurology,Molecular Biology,General Neuroscience

Reference71 articles.

1. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF;Aebischer;Hum. Gene Ther.,1996

2. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients;Aebischer;Nat. Med.,1996

3. Selective and rapid uptake of adeno-associated virus type 2 in brain;Bartlett;Hum. Gene Ther.,1998

4. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson’s disease using GDNF;Bensadoun;Exp. Neurol.,2000

5. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease;Bilang-Bleuel;Proc. Natl. Acad. Sci. USA,1997

Cited by 293 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. All-RNA-mediated targeted gene integration in mammalian cells with rationally engineered R2 retrotransposons;Cell;2024-08

2. Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications;Advanced Drug Delivery Reviews;2024-08

3. Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2‐GDNF in a Patient with Parkinson's Disease;Movement Disorders;2024-05-08

4. Microglia cells treated with synthetic vasoactive intestinal peptide or transduced with LentiVIP protect neuronal cells against degeneration;European Journal of Neuroscience;2024-02-21

5. Neurotrophic Factors in Parkinson’s Disease: Clinical Trials;Stem Cell Biology and Regenerative Medicine;2024